Global Urethral
Stricture Treatment Market, by Type (Posterior Urethral Stricture and
Anterior Urethral Stricture), by Treatment (Urethral Dilation, Direct Vision
Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and
Substitution Urethroplasty), and Others), by Disease Indication (Iatrogenic,
Idiopathic, Infection-induced, Trauma, and Others), by End User (Hospitals,
Ambulatory Surgical Center, and Others), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be
valued at US$ 1,326.0 million in 2019, and is expected to exhibit a CAGR of
6.0%, during the forecast period (2019-2027), as highlighted in a new report
published by Coherent Market Insights.
Technological advancement for
improving success rate and to lower pain with quick recovery are factors
boosting growth of the market. Tissue engineering is one of the current trends
in the treatment of urethral stricture. MukoCell, a graft for urethroplasty,
developed by UroTiss Europe GmbH is proving as breakthrough option in tissue
engineering. Increasing number of anterior urethral stricture cases is expected
to be a major factor for growth of the market. According to the National Center
for Biotechnology Information (NCBI), in 2019, around 1,242 bulbar urethral
strictures were treated with 14 different surgical techniques in Italy. The
overall success rate ranged from 87.5% to 14.3% using different techniques.
Anterior urethral stricture are the most commonly occurring stricture and are
caused due to infection or trauma leading to spongiofibrosis. Anterior urethral
stricture mostly occurs in the bulbar urethra which represents around 46.9% of
strictures, penile shares around 30.5%, penile & bulbar may represent 9.9%,
and panurethral is least representing 4.9% strictures.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2381
Browse 45 Market Data Tables and
37 Figures spread through 195 Pages and in-depth TOC on 'Global Urethral
Stricture Treatment Market, by Type (Posterior Urethral Stricture and Anterior
Urethral Stricture), by Treatment (Urethral Dilation, Direct Vision Internal
Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and Substitution
Urethroplasty), and Others), by Disease Indication (Iatrogenic, Idiopathic,
Infection-induced, Trauma, and Others), by End User (Hospitals, Ambulatory
Surgical Center, and Others), and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'
Urethroplasty is a technique used
for reconstruction of the infected section of the urethra. According to the
Columbia University Irving Medical Center Department of Urology, Urethroplasty
is considered as the ‘gold standard’ for urethral reconstruction, as it offers
long-lasting results. Urethroplasty has transformed medical procedures by
offering benefits such as lower chances of relapse of urethral stricture,
reduced threat of inflammation in the area, and improved quality of life.
According to the British Association of Urological Surgeons (BAUS) Limited,
urethroplasty is the most preferred procedure globally, with a success rate of
over 85.0%.
Moreover, adoption of inorganic
strategies such as collaborations and acquisitions by major players in the
urethral stricture treatment market are expected to drive growth of the market.
For instance, in December 2018, Amecath Medical Technologies announced the
expansion of its business in Paraguay in collaboration with Infinity
International, a healthcare service provider based in Latin America to cater to
the growing demand for urological disease treatment.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/urethral-stricture-treatment-market-2381
Furthermore, increasing product
approvals by regulatory authorities is also expected to drive the market
growth. For instance, in April 2018, Urotronic, Inc. received the U.S. Food and
Drug Administration approval for Optilume drug-coated balloon (DCB) catheter
for the treatment of male patients suffering from urethral strictures.
Key Takeaways of the Global Urethral
Stricture Treatment Market:
The global urethral stricture
treatment market is expected to exhibit a CAGR of 6.0% during the forecast
period (2019-2027), owing to increasing product launches. For instance, in
February 2017, Cook Medical, a subsidiary of Cook Group, added two new sets of
ureteral stents for percutaneous urinary drainage in its Universa product
portfolio. The Universa brand of urinary drainage products also includes
ureteral stents and Foley catheters that are available in multiple sizes and
configurations to meet patient needs and physician preference.
Increasing clinical trials by key
players are also estimated to drive the growth of the global urethral stricture
treatment market over the forecast period. For instance, in June 2018,
Urotronic Inc. collaborated with ClinLogix. LLC to initiate a clinical trial
study to establish the safety and effectiveness of the Optilume Stricture Drug
Coated Balloon (DCB). The study is expected to complete in November 2024.
Major players operating in the
global urethral stricture treatment market include Becton, Dickinson and
Company, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, Allium
Ltd., SURGIMEDIK, Cook Group, Taewoong Medical Co., Ltd., Teleflex
Incorporated, B. Braun Melsungen AG, Coloplast A/S, Boston Scientific
Corporation, and Pnn Medical A/S.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2381
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment